SalvaRx recently completed its second investment: the group bought a 9.2% stake in US-based Intensity Therapeutics Inc., a private biotechnology company developing novel approaches to treating cancer. Also, iOx (SalvaRx’s first portfolio company) announced that one of its programmes received substantial grant financing, as part of a research consortium. Consequently, SalvaRx now has exposure to three programmes which are funded through early clinical trials. We increased our price targe
